Dissolution Enhancement in Nano/Micro-Sized Dispersions of Piroxicam with the Novel Polymer Soluplus® and Polyvinyl Pyrrolidone

Authors

  • Sandeep Patnaik Department of Physics, Sri Sathya Sai Institute of Higher Learning, Prasanthi Nilayam, India
  • Muralikrishna Molli Department of Physics, Sri Sathya Sai Institute of Higher Learning, Prasanthi Nilayam, India
  • R. Gowrishankar Department of Physics, Sri Sathya Sai Institute of Higher Learning, Prasanthi Nilayam, India
  • Tanu Mimani Rattan Department of Physics, Sri Sathya Sai Institute of Higher Learning, Prasanthi Nilayam, India Nunano Solutions, Bengaluru, India
  • K. Venkataramaniah Department of Physics, Sri Sathya Sai Institute of Higher Learning, Prasanthi Nilayam, India

DOI:

https://doi.org/10.37591/(rrjops).v3i1.934

Abstract

 

Piroxicam, a Non-Steroidal Anti-Inflammatory Drug (NSAID), belongs to the class II of the biopharmaceutical classification system (BCS) and thus exhibits poor bioavailability. In an effort to tackle this issue, we report here the comparative properties of the solid dispersions of piroxicam made from a novel graft copolymer of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol (Soluplus) and the linear polymer polyvinyl pyrrolidone (K 25), both the dispersions synthesized identically using solvent evaporation method. The absence of crystallinity of drug in the solid dispersions was confirmed by Powder X-Ray Diffractometry, and Differential Scanning Calorimetry (DSC). FTIR analysis showed the presence of intermolecular hydrogen bonding between the piroxicam and the polymers. The morphology and the particle size of the dispersions were analyzed with an FESEM. The results obtained from these analyses confirm that the drug is present in amorphous state in the dispersions. The in vitro dissolution characteristics of the tablets made from these powders were studied using the USP paddle dissolution apparatus (type II). The dissolution profiles show that the nanodispersions have higher dissolution rate than that of pure drug.

Keywords: Piroxicam, solid dispersions, dissolution enhancement, polyvinyl pyrrlidone, Soluplus

Downloads

Published

2021-01-14

Issue

Vol 1-3, No 1 (2010-12)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.